#United States #New York #Rosen Law Firm #Soleno Therapeutics #SLNO

Rosen Law Firm's Class Action Investigation of Soleno Therapeutics

On September 22, 2025, the Rosen Law Firm, a prominent global attorney firm dedicated to protecting investors' rights, announced its ongoing investigation into Soleno Therapeutics, Inc. (NASDAQ: SLNO). The focus of this inquiry stems from troubling allegations that the company possibly disseminated materially misleading information concerning its business practices.

Background of the Investigation

Recently, shares of Soleno Therapeutics experienced a notable decline following a critical report published by Scorpion Capital. This report, released on August 15, 2025, raised alarms about Soleno’s newly approved treatment for Prader-Willi syndrome, VYKAT XR. The report expressed significant concerns regarding the safety of this treatment, implying that it could either be withdrawn from the market or face a substantial drop in new prescriptions due to raised safety issues.

After the release of this damaging report, Soleno's stock plummeted by 7.4% on the same day and further declined by an additional 4.9% in the subsequent trading session. Such a dramatic downturn in stock value has triggered worries among shareholders and has led to the initiation of this class action investigation.

Your Rights as an Investor

If you are among those who purchased Soleno Therapeutics' securities, you may qualify for monetary compensation without incurring any out-of-pocket expenses, thanks to a contingency fee structure proposed by the Rosen Law Firm. The firm is gearing up to launch a class action lawsuit to seek recovery of investor losses, aiming to help those affected by this significant decline.

To further explore your options, interested investors can sign up for the prospective class action by visiting Rosen Legal or contacting Phillip Kim, Esq., via the toll-free number 866-767-3653 or email at [email protected] for further assistance.

Why Choose Rosen Law Firm?

Rosen Law Firm prides itself on its impressive track record and expertise in handling securities class actions and shareholder derivative cases. With a history of successfully obtaining significant settlements, the firm has been recognized for its leadership and accomplishments. As an illustration, the Rosen Law Firm achieved the largest settlement of a securities class action from a Chinese company at the time. In 2017, it was ranked number one by ISS Securities Class Action Services based on the number of settlements, consistently placing in the top rankings since.

In 2019, the firm secured over $438 million for its clients, showcasing its dedication to recovering investor losses. Furthermore, Laurence Rosen, the founding partner, was designated as a 'Titan of the Plaintiffs' Bar' by Law360 in 2020. Many attorneys from the firm have also gained notable recognition from reputable sources like Lawdragon and Super Lawyers.

Follow the Rosen Law Firm for ongoing updates on future developments and insights through their LinkedIn, Twitter, and Facebook pages.

Conclusion

In light of these serious allegations and the substantial financial implications for investors, the Rosen Law Firm urges all shareholders of Soleno Therapeutics to take proactive measures. If you are affected, consider your options carefully and seek appropriate legal advice to ensure your rights are protected.

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Phone: (212) 686-1060
Toll-Free: (866) 767-3653
Email: [email protected]
Website: www.rosenlegal.com